Brief: Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General Hospital
16/03/2026 12:17
March 16 (Reuters) - Alzamend Neuro Inc ALZN.O: ALZAMEND NEURO INITIATES PHASE II CLINICAL TRIAL OF AL001 "LITHIUM IN BRAIN" STUDY IN PATIENTS WITH BIPOLAR DISORDER IN COLLABORATION WITH MASSACHUSETTS GENERAL HOSPITAL Source text: ID:nPn8tpPyCa Further company coverage: ALZN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview